REGENXBIO (NASDAQ:RGNX) and Dogwood Therapeutics (NASDAQ:DWTX) Head-To-Head Review

Dogwood Therapeutics (NASDAQ:DWTX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Valuation and Earnings

This table compares Dogwood Therapeutics and REGENXBIO”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26 million	($18.90)	-0.11
REGENXBIO	$170.44 million	2.58	-$193.88 million	($3.76)	-2.27

Dogwood Therapeutics has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Dogwood Therapeutics has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Profitability

This table compares Dogwood Therapeutics and REGENXBIO’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-2,027.44%	-31.29%
REGENXBIO	-113.75%	-103.12%	-37.83%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Dogwood Therapeutics and REGENXBIO, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1	0	1	0	2.00
REGENXBIO	1	1	8	0	2.70

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 468.72%. REGENXBIO has a consensus target price of $27.50, indicating a potential upside of 222.39%. Given Dogwood Therapeutics’ higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than REGENXBIO.

Insider and Institutional Ownership

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 0.2% of Dogwood Therapeutics shares are held by insiders. Comparatively, 12.8% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

REGENXBIO beats Dogwood Therapeutics on 7 of the 13 factors compared between the two stocks.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.